Vera Therapeutics (VERA) Set to Release Earnings on Thursday

Key Points

• Vera Therapeutics is expected to report Q3 2026 results after market close on November 5. Analysts forecast a loss of $1.61 per share and revenue of $3.90 million; the company previously exceeded EPS expectations by $0.06.
• Analyst sentiment is broadly positive, with a consensus “Moderate Buy” rating and an average price target of $76.86, despite ratings ranging from Sell to Strong Buy.
• VERA shares opened at $30.94, well below their 52-week high of $56.05. CEO Marshall Fordyce recently sold 18,500 shares under a pre-arranged trading plan, while insiders retain a 15.9% ownership stake.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) is projected to release its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to post earnings of ($1.61) per share and revenue of $3.90 million for the quarter. Parties are encouraged to explore the company's upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last released its earnings results on Monday, August 10th. The company reported ($1.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.58) by $0.06. During the same quarter last year, the firm earned ($1.20) earnings per share. On average, analysts expect Vera Therapeutics to post ($6.45) EPS for the current fiscal year and ($4.55) EPS for the next fiscal year.

Vera Therapeutics Stock Performance

Shares of VERA stock opened at $30.94 on Thursday. Vera Therapeutics has a one year low of $23.05 and a one year high of $56.05. The company has a debt-to-equity ratio of 0.18, a quick ratio of 10.92 and a current ratio of 10.92. The company has a 50 day moving average price of $32.04 and a 200 day moving average price of $37.26. The firm has a market capitalization of $2.23 billion, a price-to-earnings ratio of -5.28 and a beta of 1.06.

Analyst Ratings Changes

A number of research firms recently issued reports on VERA. Weiss Ratings reissued a "sell (d-)" rating on shares of Vera Therapeutics in a research report on Thursday, October 15th. Raymond James Financial reaffirmed a "strong-buy" rating on shares of Vera Therapeutics in a research report on Monday. JPMorgan Chase & Co. lifted their price target on shares of Vera Therapeutics from $76.00 to $83.00 and gave the company an "overweight" rating in a research report on Tuesday, September 8th. TD Cowen reiterated a "buy" rating on shares of Vera Therapeutics in a research note on Tuesday, September 15th. Finally, Leerink Partners initiated coverage on shares of Vera Therapeutics in a research report on Monday, October 12th. They issued a "market perform" rating and a $34.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $76.86.

Insider Activity at Vera Therapeutics

In related news, CEO Marshall Fordyce sold 18,500 shares of the firm's stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $37.00, for a total transaction of $684,500.00. Following the sale, the chief executive officer directly owned 235,244 shares in the company, valued at approximately $8,704,028. This trade represents a 7.29% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 15.90% of the company's stock.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc is a clinical-stage biotechnology company focused on developing treatments for immunological diseases. The company's research is centered on therapies that target the underlying causes of autoimmune conditions rather than primarily addressing their symptoms.

Vera's lead product candidate is atacicept, a biologic designed to inhibit the B-cell survival factors BLyS and APRIL. The company has been evaluating atacicept in IgA nephropathy, an autoimmune kidney disease that can lead to progressive loss of kidney function, and has also investigated its potential in other immune-mediated diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.